source · text/markdown
source_8c978abccc564892
sha256 5132babade05b2f4b77a218f0339b704bf8eda65e849fbd6af2c1de298944012
by researka:v2 · 2026-06-14 09:33:17.518025+04:00
# Research Synthesis: Telomere Biomarker Effects — full paper ## Abstract Evidence-honesty note: 24/26 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on telomere biomarker effects across 26 accepted source papers and 938 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 0 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, immune and inflammation, mortality and survival outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that telomere biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_biomarker_effects-v06-DAILY-2026-06-14T04-56-17Z-R2`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-14. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `telomere biomarker effects aging` - `telomere biomarker effects older adults` - `telomere biomarker effects randomized controlled trial` - `telomere aging` - `telomere older adults` - `telomere randomized controlled trial` - `biomarker aging` - `biomarker older adults` - `biomarker randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses telomere biomarker effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 179 records in the receipt-candidate union, 59 were classified as source candidates and 26 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 179 | | Classified source candidates | 59 | | No extractable claims | 21 | | None-only claim binding | 7 | | Mixed partial-or-none claim-binding candidates | 68 | | Partial-only claim-binding candidates | 22 | | Strict high-confidence sources | 2 | | Admitted final sources | 26 | ### Exclusion reasons - Non-traceable findings (claim could not be linked to source text): 0 records. - Wrong population / off-topic sources excluded at screening. - Duplicate records deduplicated by DOI / PMID before screening. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Contextual Adjacent Evidence | n=14; claims=448 | no extracted directional signal in 12/14 sources | 7 indirect; 7 review | limited corpus depth in this outcome class | | Immune and Inflammation | n=5; claims=214 | no extracted directional signal in 5/5 sources | 3 indirect; 2 review | limited corpus depth in this outcome class | | Mortality and Survival | n=2; claims=189 | no extracted directional signal in 2/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class | | Cardiometabolic | n=1; claims=7 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Dosing and Pharmacokinetics | n=1; claims=24 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Frailty | n=1; claims=7 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Muscle Function | n=1; claims=14 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Safety and Comorbidity | n=1; claims=35 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Contextual Adjacent Evidence Outcomes 14 included sources were assigned to this outcome class. Directional coding: mixed=1, null=12, unclear=1. Directness coding: indirect=7, review=7. ### Immune Inflammation Outcomes 5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, review=2. ### Mortality Survival Outcomes 2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1. ### Cardiometabolic Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1. ### Dosing Pharmacokinetics Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ### Frailty Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ### Muscle Function Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1. ### Safety Comorbidity Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus does not include a long-term, well-powered randomized controlled trial in non-diabetic community-dwelling adults powered for hard clinical endpoints such as all-cause mortality, cardiovascular events, or incident frailty. As a result, the headline conclusion that the anti-aging case remains incomplete is supported only by indirect and observational evidence, and any inference about whether modifying telomere length in healthy adults would change morbidity or mortality cannot be grounded in the present corpus. Several clinically relevant outcomes are touched by only a single source, so the within-corpus replication that would normally anchor a synthesis-level claim is absent. Because each of these findings rests on a single observational dataset, neither can be cross-validated against an independent source, and the corresponding effect estimates should be treated as hypothesis-generating rather than confirmatory. The enrolled populations are narrowly distributed across a few clinical and demographic strata, and external validity beyond those strata cannot be assumed. For several clinically attractive claims, the corpus supplies only mechanistic or indirect evidence and no direct in-human demonstration. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support telomere biomarker effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 26 included sources on Telomere Biomarker Effects across 8 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 26 curated reference papers, the evidence base for Telomere Biomarker Effects shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The Telomere Biomarker Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | cardiometabolic | 0 | 1 | null | direct interventional hard-endpoint gap | | frailty | 0 | 1 | null | direct interventional hard-endpoint gap | | muscle function | 0 | 1 | null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 14 | mixed, null, unclear | direct interventional hard-endpoint gap | | dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap | | immune and inflammation | 0 | 5 | null | direct interventional hard-endpoint gap | | mortality and survival | 0 | 2 | null | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 1 | null | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P4 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 14 indirect sources; direction profile: mixed, null, unclear | | P5 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | ### Next-Study Design Recommendation The next high-yield study for Telomere Biomarker Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Young 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001. - Sasmita 2025; tier=B2; directness=review; endpoint=mortality survival; direction=null; representative statistic=P = 0.01. - Su 2025; tier=B2; directness=review; endpoint=immune inflammation; direction=null; representative statistic=P < 0.00001. - Yang 2025; tier=B2; directness=indirect; endpoint=mortality survival; direction=null; representative statistic=P < 0.001. - Wolkowitz 2011; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P < 0.01. - Fuente 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001. - Farhat 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.12. - Ishii 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.028. - Wattanathorn 2025; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P < 0.01. - Ismail 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Role of telomere length and telomerase activity in accelerated cellular aging and major depressive disorder: a systematic review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=129. - Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis: outcome=mortality survival; directness=review; tier=B2; direction=null; claims=113. - Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis: outcome=immune inflammation; directness=review; tier=B2; direction=null; claims=99. - Determinants of temporal change in telomere length and its associations with chronic complications and mortality in type 2 diabetes: the Fremantle diabetes study phase II: outcome=mortality survival; directness=indirect; tier=B2; direction=null; claims=76. - Leukocyte Telomere Length in Major Depression: Correlations with Chronicity, Inflammation and Oxidative Stress - Preliminary Findings: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=60. - Beneficial Effects of a Moderately High-Protein Diet on Telomere Length in Subjects with Overweight or Obesity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=51. - Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=42. - Relationship between telomere length and postoperative delirium: a single center prospective observational pilot study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=40. - An Anthocyanin- and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=40. - Exploring the association between depression and telomere length: A systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=35. - Association Between Telomere Shortening and Erythropoietin Resistance in Patients with Chronic Kidney Disease Undergoing Hemodialysis: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=35. - Telomere dynamics are influenced by sleep, sleep variability and circadian rhythms in older adults with or without alzheimer’s risk: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31. - Platelet-to-lymphocyte ratio and telomere length in older adults: An inverted U-shaped nonlinear relationship: A nationwide cohort study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31. - Associations of Midlife Leukocyte Telomere Length With Measures of Left Atrial Function in Community‐Dwelling Older Adults: The ARIC Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=25. - Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=24. - Frailty is associated with the epigenetic clock but not with telomere length in a German cohort: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=22. - Exercise delays aging: evidence from telomeres and telomerase —a systematic review and meta-analysis of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=18. - Shorter Telomeres and Faster Telomere Attrition in Individuals With Five Syndromic Forms of Intellectual Disability: A Systematic Review and Meta‐Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=16. - A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance: outcome=muscle function; directness=review; tier=B2; direction=null; claims=14. - Infection and telomere length: A systematic review: outcome=immune inflammation; directness=review; tier=B2; direction=null; claims=8. - Gender-based differences in telomere attrition and long-term respiratory dysfunction in COVID-19 ICU survivors one year post-infection: implications for aging-associated pulmonary decline: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=7. - Effect of infections, DNA methylation and telomere length on frailty trajectories in hospitalized older patients: the INFRAGEN study protocol: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=7. - The association of serum levels of vitamin D with leucocyte telomere length, as a marker of biological aging: A meta-analysis: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=7. - A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3. - Parental Age Effects on Offspring Telomere Length Across Vertebrates: A Meta‐Analysis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=3. - Effect of Physical Exercise on Telomere Length: Umbrella Review and Meta-Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=2. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - No load-bearing cross-study disagreements were detected. ## Conclusion For telomere biomarker effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Murillo-Ortiz 2025, Liu 2025, Lehodey 2025, Parikh 2025, Kim 2025, Breitling 2016, Sun 2025, Hanley 2025, Ryall 2025, Tunnicliffe 2025, Guo 2025, Behar-Lagares 2026, Shen 2026, Vlasova 2026, Gerede 2026, Sanchez-Gonzalez 2025. ## References - **Young 2025.** _Role of telomere length and telomerase activity in accelerated cellular aging and major depressive disorder: a systematic review._ Molecular Psychiatry, 2025. DOI: 10.1038/s41380-025-03296-3. PMID: 41053437. - **Sasmita 2025.** _Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis._ Exploration of Targeted Anti-tumor Therapy, 2025. DOI: 10.37349/etat.2025.1002289. PMID: 40061142. - **Su 2025.** _Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis._ Cell Biology and Toxicology, 2025. DOI: 10.1007/s10565-025-10115-6. PMID: 41286474. - **Yang 2025.** _Determinants of temporal change in telomere length and its associations with chronic complications and mortality in type 2 diabetes: the Fremantle diabetes study phase II._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02832-3. PMID: 40611236. - **Wolkowitz 2011.** _Leukocyte Telomere Length in Major Depression: Correlations with Chronicity, Inflammation and Oxidative Stress - Preliminary Findings._ PLoS ONE, 2011. DOI: 10.1371/journal.pone.0017837. PMID: 21448457. - **Fuente 2025.** _Beneficial Effects of a Moderately High-Protein Diet on Telomere Length in Subjects with Overweight or Obesity._ Nutrients, 2025. DOI: 10.3390/nu17020319. PMID: 39861449. - **Farhat 2025.** _Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial._ Nutrients, 2025. DOI: 10.3390/nu17182974. PMID: 41010500. - **Ishii 2025.** _Relationship between telomere length and postoperative delirium: a single center prospective observational pilot study._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-10288-4. PMID: 40628895. - **Wattanathorn 2025.** _An Anthocyanin-and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms262210911. PMID: 41303396. - **Murillo-Ortiz 2025.** _Association Between Telomere Shortening and Erythropoietin Resistance in Patients with Chronic Kidney Disease Undergoing Hemodialysis._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26073405. PMID: 40244253. - **Ismail 2025.** _Exploring the association between depression and telomere length: A systematic review and meta-analysis._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-07076-5. PMID: 40595131. - **Liu 2025.** _Platelet-to-lymphocyte ratio and telomere length in older adults: An inverted U-shaped nonlinear relationship: A nationwide cohort study._ Medicine, 2025. DOI: 10.1097/MD.0000000000044188. PMID: 40958330. - **Lehodey 2025.** _Telomere dynamics are influenced by sleep, sleep variability and circadian rhythms in older adults with or without alzheimer’s risk._ Alzheimer's Research & Therapy, 2025. DOI: 10.1186/s13195-025-01923-3. PMID: 41345970. - **Parikh 2025.** _Associations of Midlife Leukocyte Telomere Length With Measures of Left Atrial Function in Community‐Dwelling Older Adults: The ARIC Study._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2025. DOI: 10.1161/JAHA.124.040459. PMID: 40767284. - **Kim 2025.** _Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms._ Nutrients, 2025. DOI: 10.3390/nu17121983. PMID: 40573097. - **Breitling 2016.** _Frailty is associated with the epigenetic clock but not with telomere length in a German cohort._ Clinical Epigenetics, 2016. DOI: 10.1186/s13148-016-0186-5. PMID: 26925173. - **Sun 2025.** _Exercise delays aging: evidence from telomeres and telomerase —a systematic review and meta-analysis of randomized controlled trials._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1627292. PMID: 40642293. - **Hanley 2025.** _Shorter Telomeres and Faster Telomere Attrition in Individuals With Five Syndromic Forms of Intellectual Disability: A Systematic Review and Meta‐Analysis._ Journal of Intellectual Disability Research, 2025. DOI: 10.1111/jir.13244. PMID: 40274277. - **Ryall 2025.** _A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf068. PMID: 40247641. - **Tunnicliffe 2025.** _Infection and telomere length: A systematic review._ PLOS One, 2025. DOI: 10.1371/journal.pone.0333107. PMID: 40986533. - **Guo 2025.** _Effect of infections, DNA methylation and telomere length on frailty trajectories in hospitalized older patients: the INFRAGEN study protocol._ BMC Geriatrics, 2025. DOI: 10.1186/s12877-025-06194-z. PMID: 40702442. - **Behar-Lagares 2026.** _Gender-based differences in telomere attrition and long-term respiratory dysfunction in COVID-19 ICU survivors one year post-infection: implications for aging-associated pulmonary decline._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2025.1681454. PMID: 41567226. - **Shen 2026.** _The association of serum levels of vitamin D with leucocyte telomere length, as a marker of biological aging: A meta-analysis._ Medicine, 2026. DOI: 10.1097/MD.0000000000044487. PMID: 41650046. - **Vlasova 2026.** _Parental Age Effects on Offspring Telomere Length Across Vertebrates: A Meta‐Analysis._ Molecular Ecology, 2026. DOI: 10.1111/mec.70215. PMID: 41556533. - **Gerede 2026.** _A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives._ Medical Sciences, 2026. DOI: 10.3390/medsci14010100. PMID: 41892815. - **Sanchez-Gonzalez 2025.** _Effect of Physical Exercise on Telomere Length: Umbrella Review and Meta-Analysis._ JMIR Aging, 2025. DOI: 10.2196/64539. PMID: 39846264.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "9287ca24-b2d9-49ae-a044-a9bc509ff1e3",
"title": "Research Synthesis: Telomere Biomarker Effects \u2014 full paper"
}